DaVita Inc. (NYSE:DVA) Shares Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its position in DaVita Inc. (NYSE:DVA) by 30.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,224 shares of the company’s stock after purchasing an additional 1,465 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in DaVita were worth $956,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DVA. Transcendent Capital Group LLC purchased a new stake in DaVita during the third quarter worth approximately $25,000. Blue Trust Inc. boosted its position in DaVita by 56.4% during the 3rd quarter. Blue Trust Inc. now owns 330 shares of the company’s stock worth $54,000 after purchasing an additional 119 shares during the period. Quarry LP acquired a new stake in DaVita in the 3rd quarter valued at $60,000. Versant Capital Management Inc raised its position in DaVita by 58.7% in the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after purchasing an additional 169 shares during the period. Finally, ORG Wealth Partners LLC acquired a new position in shares of DaVita during the third quarter worth about $97,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Performance

NYSE:DVA opened at $173.69 on Wednesday. DaVita Inc. has a 1-year low of $108.76 and a 1-year high of $179.60. The stock has a market cap of $14.24 billion, a P/E ratio of 18.74, a PEG ratio of 0.84 and a beta of 0.93. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The firm has a 50-day moving average of $160.98 and a two-hundred day moving average of $157.00.

Wall Street Analysts Forecast Growth

Separately, Barclays raised their target price on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, DaVita presently has a consensus rating of “Hold” and a consensus price target of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.